Finally, the ADAURA trial, a phase III trial comparing adjuvant osimertinib to SOC, demonstrated an improvement in DFS and OS for patients with EGFR mutant NSCLC (9, 10). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.